Shunji Haruta
Chief Tech/Sci/R&D Officer presso SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Profilo
Shunji Haruta has worked as a Director at Satsuma Pharmaceuticals, Inc. since 2023 and as an Executive Officer & Research Manager at Shin Nippon Biomedical Laboratories, Ltd.
since 2001.
Posizioni attive di Shunji Haruta
| Società | Posizione | Inizio |
|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
| SATSUMA PHARMACEUTICALS, INC. | Director/Board Member | 08/06/2023 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Aziende private | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Shunji Haruta
